Immunology Dermato/Rheumatology - 2 Marketed brands : Stelara (iIL12/23), Tremfya (first in class iIL23)(Psoriasis, Psoriatic Arthritis) ; Turn-over > $1.3Bn- Portfolio of indications under development - 3 pipeline drugs (oral IL23i peptide, IL17i SM, 1st in class fix dose combination therapy)• Member of J&J EMEA Strategy and operations Organization • Responsible for designing, developing and rolling out European strategy for Therapeutic area brand portfolio • Responsible for driving regional operations to support competitiveness of in-line brands in one of the most competitive pharma market• Integrated Brand Value Team (IBVT) leader- Leader of an European cross functional team including Marketing, Medical affairs, Health economy and Market access, Business intelligence and business analysis, regulatory and key countries business leaders.- Work at establishing JANSSEN as indisputable leader and pave the way to expand its leadership in the therapeutic area• Close collaboration with Global Strategic Organization as part of the Global commercial network - Shape global strategy and R&D plan to ensure successful access and launch in EMEA - Co-create global commercial portfolio strategy• Schizophrenia Long Acting (ending 07/20)- 3 brands ; Turnover >$1Bn

General Manager of Janssen’s operating company in Algeria. (80 people)Responsible for driving operations and shaping the organization to sustain long term growth on a critically important emerging market.Full P&L responsibility Mission & Achievments :- Ensure business growth of JNJ innovative portfolio in a highly complex and unpredictibal business environement - Work at sustaining operations in a volatile regulation framework : Evolution of company legal footprint by setting new sustainalble legal entity- Market access and shape policies for innovation : successful negotiations despite locked out context- Create partnership for localizing drug manufacturing : Localized product portfolio extension (oncology and high potent products)- Lead Company transformation and restructuring : new organization, new jobs, new business and corporate mindset- Lead and restructure Algeria management team that includes Business Unit managers, head of Med Affairs , Head of Market Access, Head of Reg Affairs, HCCO and gov Affairs- Member of NEMA leadership team (Near East Maghreb and Africa Management board)

Management of promotional and sales network for solid tumor brandsManagement of distric sales managersResponsible for driving Janssen’ competitivness in a highly competitive market by strengthening sales force effectiveness, continuously developing commercial skills and leading teams towards customer interaction excellence.Change management

Country Value Team Leader - Lead of a cross functional team including Med.affairs, health economy and market access, business intelligence, finance, regulatoryPortfolio (>230M€): Prostate Cancer (Zytiga); Ovarian and Breast Cancer (Caelyx); Anemia (Eprex)Priority brand - Business maximizationMature brands - Late Life cycle management Customer and patient pathway orientation Management of 5 people (3 product managers)People developpment

Prostate cancer

Alzheimer's disease

HIV